This study will determine the feasibility of using the point of care Toxoplasma ICT IgG-IgM BK test produced by LD Bio Diagnostic to detect Toxoplasma gondii in clinical settings. The result of testing from Toxoplasma ICT IgG-IgM BK test will be compared with the standard predicate test. These results will be provided to FDA for consideration for clearance of this test.
Age
18–90
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
any adult who is willing to participate in the study
You may not be if
pregnant women who are in their 17-27 weeks of gestation.
Clareo Health | Point of Care Testing for Presence of Current and or Previous T. Gondii Infection
